Please assess the completion status of the following clinical trial:

Trial Title: Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children, 18-24 months of age~* Subjects who had completed the primary series of Pentabio vaccine in the previous trial~* Father, mother, or legally acceptable representative have been informed properly regarding the study and signed the informed consent form~* Subject's parents commit to comply with the instruction~Exclusion Criteria:~* Subjects concomitantly enrolled or scheduled to be enrolled in another trial~* Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature \>=37.5oC on Day 0)~* Known history of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection~* Known history of allergy to any component of the vaccines (e.f. formaldehyde)~* Known history of acquired immunodeficiency (including HIV infection)~* Subject who has received a treatment likely to alter immune response in the previous 4 weeks (e.g intravenous immunoglobulin, blood-derived products or long term corticotherapy (\>2 weeks)~* Subject receives other vaccination within 1 month prior to inclusion~* Any abnormality or chronic disease justified by investigator that might interfere assessment of the trial objectives~* Infant with a known history of diphtheria, tetanus, pertussis, Hepatitis B and Hib infection

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- Pentavalen (Type: EXPERIMENTAL): Pentabio Vaccine One dose corresponds to 0.5ml The vaccine shall be given intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).